R-Pharm raised 50 million euros for the production of AstraZeneca vaccine and the drug against COVID-19 in Germany

2021

R-Pharm raised 50 million euros for vaccine production AstraZeneca

On November 10, 2021, it became known that Raiffeisen Bank and R-Farm entered into a three-year loan agreement in the amount of 50 million euros. The investment loan will be aimed at expanding the production capacity of the pharmaceutical company's plant in the German city of Illertissen.

It is reported that additional capacity is needed by P-Pharm in order to deploy the production of the most biopharmaceutical drugs, in particular, anticovid (COVID-19) vaccines and drugs for a wide range of diseases based on monoclonal antibodies. After the approval of the Russian coronavirus vaccine Sputnik V by the European Medical Agency (EMA), new production lines will expand the export supply of Russian vaccine, R-Pharm said in a statement.

R-Pharm raised 50 million euros for the production of AstraZeneca vaccine and the drug against COVID-19 in Germany

Until permission is received from the European regulator, R-Pharm will produce the Vaxzevria vaccine from AstraZeneca at the site in Germany, Kommersant sources say. By November 10, 2021, R-Pharm releases this vaccine on its site in the Moscow technopolis exclusively for export to the EU and third countries where the drug is allowed for use, the source explains. DSM Group CEO Sergei Shulyak agrees with him: according to him, it is logical if R-Pharm begins production of a vaccine against British AstraZeneca in Germany, since the company already has technologies for producing the drug.

It will be necessary to wait for the approval of a domestic drug in the EU until about 80% of the population is vaccinated with local vaccines, predicts Nikolai Bespalov, development director of RNC Pharma.

According to the manufacturer's calculations, with the full capacity of the line, up to 150 million doses of vaccine per year will be produced. Along with the vaccine, the plant will also produce Artlegia's rheumatoid arthritis drug, which has proven well in treating patients with coronavirus. The start of production is scheduled for January 2022.^[1]

Start of vaccine production for export

In mid-September 2021, the production of a vaccine for coronavirus began in Russia. COVID-19 AstraZeneca Company "" R-Pharm makes the drug under license University of Oxford for export purposes.

In Russia, foreign vaccines are already being produced at R-Farm AstraZeneca they are being produced quite under export contracts, "Vasily Osmakov, first deputy head of the Ministry of Industry and Trade, told reporters (quoted by RIA Novosti).

Production of COVID-19 AstraZeneca vaccine for export started in Russia

According to him, the domestic market will continue to use domestic vaccines.

Everything is possible, especially in the future, but here and now, in the wake of hype demand, we work with our industries, support our pharma, "he added.

The vaccine is produced at the R-Pharm site in accordance with an agreement that implied cooperation between R-Pharm and AstraZeneca in the field of production of a ready recombinant adenovirus vaccine and its launch in Russia if clinical trials are successful. Then the Anglo-Swedish company transferred the Russian cell line and the adenovirus vector.

R-Farm CEO Vasily Ignatiev said in May 2021 that the company plans to release the first batch of coronavirus vaccine in June 2021 under license from Oxford University and AstraZeneca. He pointed out that the entire volume of this R-Covi vaccine, which will be produced in Russia at the R-Pharm production facilities - several hundred thousand vaccines per month - will be exported.

By September 2021, AstraZeneca is also participating in clinical studies of a combination of its own vaccine and the Russian Sputnik Light, which, according to preliminary results, turned out to be safe and effective. At the same time, not a single foreign drug, including the AstraZeneca vaccine, has been registered in Russia.^[2]

The vaccine produced in Russia AstraZeneca was called "R-Covi"

March 12, 2021 it became known the name, coronavirus vaccines COVID-19 which under the license of the British pharmaceutical company AstraZeneca University of Oxford and will be produced by the Russian company "."R-Pharm

According to Sheets"" with reference to the general director of "R-farm," the Vasily Ignatiev drug was called "R-Covi." It will be manufactured only for deliveries abroad - Russia it is not planned to register a vaccine in.

The vaccine AstraZeneca produced by the Russian company R-Farm was called R-Covi

Ignatiev says that the first batch of R-Kovi is planned to be released in June 2021. At the first stage, it is planned to produce several hundred thousand doses monthly, but gradually the volumes will increase, he said.

It is planned to export to the countries of the Middle East, Europe, the Persian Gulf countries are most active, "said Vasily Ignatiev on the sidelines of the Russian Pharmaceutical Forum.

Earlier, Ignatiev said that R-Farm will provide technological capabilities and act as a hub for supplies to dozens of countries, including the Middle East, Southeast Asia, and Europe.

Earlier, AstraZeneca, NIC of Epidemiology and Microbiology named after N.F. Gamalei, RDIF and R-Pharm signed a memorandum of intent in the field of prevention COVID-19, and also announced the start of clinical research on the combination of vaccines for coronavirus infection AZD1222 and Sputnik V.

Also, judging by the data of the state register of medicines by May 2021, clinical trials of the third phase of the vaccine AstraZeneca planned in Russia with the participation of 150 people on the basis of four sites. However, Izvestia, citing a specialist from one of the sites, wrote that the tests were suspended.

AstraZeneca plans to deliver a total of 3 billion doses of vaccine worldwide by the end of 2021.^[3]

2020: R-Pharm signed a contract with AstraZeneca for the production of vaccines for COVID-19

On July 16, 2020, it became known that R-Pharm"" signed AstraZeneca a contract with the production of vaccines for, COVID-19 coronavirus which the British-Swedish company developed together with. This University of Oxford was told by the head, Russian Direct Investment Fund (RDIF) Kirill Dmitriyev commenting on the statement of the National Center cyber security Great Britain about the alleged attacks of Russian hackers on foreign organizations involved in the creation of such. vaccines

There is no need to steal anything from Oxford already because the Anglo-Swedish pharmaceutical company AstraZeneca agreed with one of the Russian portfolio companies R-Pharm to produce Oxford vaccines in Russia. That is, all information has already been transferred to the Russian manufacturer, including all technologies. This is a commercial agreement between AstraZeneca and R-Pharm, Dmitriyev said in an interview with the British Times Radio.

R-Pharm signed a contract with AstraZeneca for the production of vaccines for COVID-19

Dmitriyev regarded the charges of cyber attacks as an attempt to "tarnish the reputation of the Russian vaccine," developed in 2015 against Ebola and then modified to treat MERS, a Middle Eastern respiratory syndrome caused by one of the coronaviruses.

All this is published in scientific journals. And the only thing that scientists have done is simply replace parts of Ebola and parts of MERS with parts of coronavirus, "said the director of the RDIF, recalling the development of Russian vaccines.

On July 16, 2020, the UK National Cybersecurity Center (NCSC) reported that the hacker group APT29 made attempts to hack into data from pharmacological companies in order to steal information about the development and testing of a vaccine for coronavirus. Hackers were credited with communications with Russian intelligence. Similar statements were made by the intelligence services of the United States and Canada. The Kremlin responded by saying that Russia has nothing to do with cyber attacks.^[4]

Notes